Nurse Practitioner Chronicles

  CLINICAL PRACTICE   |   PATIENT EDUCATION & COUNSELING June 2026   |   NP Chronicles Clinical Education   Your Older Patients Are Taking More Supplements Than You Realize — And It's Getting More Complicated By Valerie Watters-Burke, DNSc, MSN, MBA, FNP-BC, GNP-BC, PPCNP-BC Based on: Lam CS et al. Emerging Patterns in Dietary Supplement Use Among US Adults, 1999–2023. JAMA Network Open. 2026;9(6):e2619291.   CLINICAL BOTTOM LINE A landmark 25-year NHANES analysis published in JAMA Network Open (June 2026) reveals that supplement use among US adults climbed from 51% in 1999 to 60% in 2023 — with the most dramatic growth in adults aged 65 and older (62% to 78%). The supplement landscape has shifted away from multivitamins toward a complex, personalized mix of vitamins, minerals, and nonvitamin/nonmineral products. For NPs, this is not a benign background trend. It is a polypharmacy story in disguise — and your patients need...

PHARMACOLOGY UPDATE   |   ANTIMICROBIAL THERAPY June 2026   |   NP Chronicles Clinical Education   Zaynich Is Here: What NPs Need to Know About the FDA's Newest Antibiotic for Complicated UTI By Valerie Watters-Burke, DNSc, MSN, MBA, FNP-BC, GNP-BC, PPCNP-BC   CLINICAL BOTTOM LINE Cefepime-zidebactam (Zaynich) received FDA approval in June 2026 for complicated UTI (cUTI) and acute pyelonephritis (AP) caused by susceptible gram-negative pathogens, including drug-resistant strains. In the pivotal Phase 3 trial, it outperformed meropenem at the primary endpoint (89% vs. 68.4%) — a clinically meaningful difference that NPs treating hospitalized patients with resistant infections need to know.   Why This Approval Matters Antimicrobial resistance is one of the defining clinical challenges of our era. For NPs working in hospital-based, telehealth urgent care, or primary care settings, complicated urinary tract infections — espe...